Genentech, Inc.

F. Hoffmann-la Roche Ag

Array Biopharma Inc.

Curis, Inc.

Piramed Limited

Janet Gunzner

Daniel P Sutherlin

Georgette M Castanedo

Simon Mathieu

Bing-Yan Zhu

Alan G Olivero

Adrian Folkes

Sally Oxenford

Irina Chuckowree

Richard A Goldsmith

Shumei Wang

Nan Chi Wan

Tim Heffron

Tracy Bayliss

Kimberly Malesky

Steven T Staben

Vickie H Tsui

Jennafer Dotson

Alexandre Joseph Buckmelter

Li Ren

David A Moreno

Ellen Ruth Laird

Christian Wiesmann

Bainian Feng

Wendy B Young

Brad Newhouse

Mark E Reynolds

Mark S Stanley

Stephen Joseph Shuttleworth

Joachim Rudolph

Jeongbeob Seo

Mark A Reynolds

Scott J Savage

Jonas Grina

Zhaoyang Wen

Tim Hancox

Michael S Dina

Liang Bao

Steven Mark Wenglowsky

Rebecca L Lalonde

Kateri Ahrendt

Joshua D Hansen

Kim Malesky

Michael F T Koehler

Hongqi Tian

Stephen Shuttleworth

Jason De Meese

Scott Savage

Paul Lunghofer

Mark Stanley

Michael F Koehler

Christian Weismann

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and Ris a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Phosphoinositide 3-kinase inhibitor compounds and methods of use

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R, R, R, R, m and n are as described herein.

Pyridyl inhibitors of hedgehog signalling

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pharmaceutical compounds

Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazole [3, 4-B] pyridine Raf inhibitors

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Raf inhibitor compounds and methods of use thereof

Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Thiazolopyrimidine PI3K inhibitor compounds and methods of use

Growing community of inventors

Berkeley, CA, United States of America

Janet Gunzner